Introduction {#sec1}
============

Sex differentiation of all somatic tissues, including the brain, is driven both by direct genetic influences and gonadal hormones with only minimal environmental effects ([@ref7]; [@ref5]; [@ref54]; [@ref41]; [@ref22]). Specifically, sex determination or the commitment of an organism to develop toward a female or male phenotype ([@ref7]) is mediated via genetic factors, most importantly the presence or absence of the testis-determining gene *Sry* on chromosome Y ([@ref2]). Morphological sex differences are reflected not only in sex-specific behavior in humans observed from early childhood onward ([@ref1]) but also in the sex-related susceptibility to neuropsychiatric disorders ([@ref4]). Although there is a consensus of a significant relationship between brain structure and behavior in the context of sex differences, the underlying mechanisms are understood only in a few cases ([@ref13]). One example is the sexually dimorphic nucleus of the preoptic area in the human brain ([@ref77]), later also called the interstitial nucleus of the anterior hypothalamus-1 (INAH-1), which is associated with male sexual behavior ([@ref58]). At the neuroanatomical level, sex differences have been repeatedly observed, in particular mean lower total intracranial volume (TIV), but larger overall cortical volume relative to cerebrum size, in female as compared to male individuals ([@ref20]; [@ref10]; [@ref64]). Additionally, the hippocampus, hypothalamus, amygdala, insula, and angular gyrus are repeatedly shown to be different for human male and female in postmortem and in vivo imaging studies ([@ref77]; [@ref20]; [@ref65]; [@ref44]).

Understanding sex differences of the brain's morphology further increases in complexity when introducing the necessary concept of gender identity ([@ref51]). While sex refers to the biological sex assigned at birth based on the anatomy of an individual's reproductive system (male or female), gender (or gender identity) indicates the personal perception of oneself belonging to a certain gender (male/female/third gender). Hence, a cisgender person exhibits a matching gender identity and assigned sex, while a transgender individual experiences discrepancies between the expression of gender and biological sex. It has been hypothesized that the transgender identity emerges from a temporal mismatch between the sexual differentiation of the brain versus the rest of the body ([@ref81]; [@ref76]). Specifically, while primary sexual characteristics develop very early in the womb (\~6th week of pregnancy) based on the presence or absence of the Y chromosome, the sexual differentiation of the brain only starts in the second trimester of pregnancy and continues until puberty ([@ref76]). Until recently, this mismatch was associated with the notion of gender identity disorder, which was relabeled as gender dysphoria by the diagnostic and statistical manual of mental disorders-5 (DSM-5) and refers to the distress experienced due to gender identity issues ([@ref16]). To fulfill diagnostic criteria, the marked incongruence between an individual's experienced gender and assigned sex must be present after the onset of puberty for at least 6 months. Of note, gender dysphoria as used in DSM-5 will be replaced by the term gender incongruence in the upcoming International Classification of Diseases-11 (ICD-11) and moved out of the mental disorders into sexual healthy conditions in order to decrease the stigma for transgender people ([@ref63]). ICD coding facilitates access to the significant health care needs associated with the condition even when not considered a mental disorder ([@ref80]). In compliance with this fundamental rethinking, we opted for the term gender incongruence to describe the condition throughout the manuscript. Gender incongruence is rare with prevalence rates ranging between 0.5% and 1.3% ([@ref84]). Transgender populations are exposed to social distress ([@ref79]), and gender incongruence has been associated with affective and anxiety disorder ([@ref27]), increased suicidality ([@ref60]), eating disorders ([@ref15]), autism spectrum disorder ([@ref57]), and substance abuse ([@ref21]) as compared to the cisgender groups. Therefore, an accurate biological characterization, early identification, and medical guidance of transgender individuals are of high clinical relevance.

The detection of structural brain patterns characterizing gender incongruence could inform these clinical applications. Several magnetic resonance imaging (MRI) studies comparing transgender with cisgender individuals described volumetric differences in biological men with female versus male gender identity, which were located in the putamen ([@ref46]), the thalamus ([@ref67]), and the angular and the insular gyrus ([@ref75]). Moreover, several authors suggest a stronger resemblance of certain brain structures in persons sharing the same gender identity ([@ref81]; [@ref18]; [@ref72]), although the greatest volumetric differences are still based on biological sex ([@ref46]; [@ref67]; [@ref72]). A comprehensive review concluded that the overall brain structure of transgender individuals was mostly similar to subjects sharing their biological sex while single regions seem to adjust to the structure of individuals sharing their gender identity ([@ref73]). The available results are equivocal in terms of the sexually differing brain regions detected and particularly regarding the direction of the divergence between sex- and gender-specific neuroanatomical correlates.

Multivariate pattern analysis (MVPA) techniques provide major chances toward the implementation of imaging biomarkers in the field of psychiatry, for example, in schizophrenia ([@ref31]), major depression ([@ref30]) and dementia ([@ref32]) (see also [@ref45]). In contrast to classical univariate analysis, MVPA provides the opportunity to delineate neuroimaging patterns that are predictive or classificatory in nature, thus allowing to overcome the merely associative evidence levels of previous group-level paradigms ([@ref14]). Furthermore, MVPA accounts for the intrinsic complex nature of the brain and the heterogeneity of psychiatric illness by evaluating the effect of different variables simultaneously ([@ref66]). To the best of our knowledge, only one study has employed MVPA techniques on gray matter (GM) volumetric data to demonstrate that individuals with the same gender identity can be better differentiated than those sharing their natal sex based on spatially distributed neuroanatomical patterns ([@ref28]). Further studies need to be performed to fully understand the interaction between biological sex and gender incongruence.

Thus, we aimed at identifying neuroanatomical models of sex and gender identity by comparing 69 cisgender and 52 hormone-naïve transgender individuals using MVPA of structural MRI data. Based on current literature, we hypothesized that 1) sex differences in brain structure present in cisgender individuals will be less expressed in transgender individuals and 2) this pattern will distinguish sexes in independent patients with major depression at similar accuracy levels as in cisgender healthy controls. Additionally, we explored whether cross-sex hormonal treatment moderates the expression of this diverging brain pattern in a longitudinal design. Moreover, we hypothesized that distinct neuroanatomical signatures of male and female gender identity as well as gender incongruence exist beyond the brain classifier of biological sex.

Materials and Methods {#sec2}
=====================

Subjects {#sec3}
--------

A total of 121 participants were included in the current study. The sample comprised 29 transgender men (TM, syn. female-to-male transgender, mean age ± SD = 27.17 ± 6.29), 23 transgender women (TW, syn. male-to-female transgender, mean age ± SD = 30.17 ± 8.24), 35 female cisgender (FC, mean age ± SD = 26.29 ± 5.90), and 34 male cisgender (MC, mean age ± SD = 27.09 ± 6.33). Transgender participants were recruited at the Department of Gynecology and Obstetrics, Unit for Gender Identity Disorder, Medical University of Vienna, Austria, while cisgender individuals were recruited via community advertisement. At the time of recruitment (2011--2015), transgender subjects met diagnostic criteria for gender identity disorder as assessed by experienced psychiatrists using the Structural Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders (SCID), fourth edition (DSM-IV) and the International Classification of Diseases, 10th revision, as well as several semistructured, sociodemographic, clinical, and psychiatric interviews based on the legal requirements for cross-sex hormonal treatment in Austria. Gender identity disorder in DSM-IV is described as a strong incongruence between a person's experienced or expressed gender and their assigned gender based on their biological sexual characteristics, which persists over \>6 months and causes clinically significant distress and daily life impairment. To avoid stigmatization and emphasize the emotional distress caused by the incongruence of belonging to- and the desire of being treated as a gender "other than the assigned gender" rather than the cross-sex identity issue per se, gender identity disorder was relabeled as gender dysphoria in DSM-5 and will be replaced by gender incongruence and moved out of the mental disorders in ICD-11. In the present sample, changes between DSM-IV and DSM-5 do not interfere with the interpretation of our results, since transgender participants explicitly reported feelings of belonging to the opposite gender to the one assigned and expressed the desire for sex reassignment. All transgender participants reported experiencing gender incongruence at a relatively early age (before or at puberty) and were hormone-naïve. All of them were free of current psychiatric comorbidities as assessed using SCID I (major mental disorders) and II (personality disorders), although some subjects reported a history of previous depressive symptoms (2 TW) and cannabis abuse (1 TW, 1 TM). One TM showed a previous history of eating and anxiety disorders. At the screening visit, all participants underwent standard medical examination, including physical examination, routine laboratory testing, and ECG, as well as a thorough anamnestic exploration. Exclusion criteria were the presence or history of any severe physical or neurological illness (and psychiatric disorders for control subjects), intake of psychotropic medication or hormones (including contraceptives), sexual development disorders (as assessed by an experienced gynecologist), pregnancy, breastfeeding, and any contraindications to magnetic resonance scanning. Sexual orientation and hormone levels were assessed for each participant (see Supplementary material). All subjects provided written informed consent and received financial reimbursement for participation. This study was approved by the Ethics Committee of the Medical University of Vienna and was performed according to the Declaration of Helsinki (internal ethics committee number 644/2010).

###### 

Demographic data of the study sample

  Group                            FC               TM              MC              TW         F/ch2        *P*
  ---------- -------------- ---------------- ---------------- --------------- --------------- -------- -------------
  *N*             121              35               29              34              23                 
  Age ± SD    27.46 ± 6.66    26.29 ± 5.90     27.17 ± 6.29    27.09 ± 6.33    30.17 ± 8.24     1.72       0.17
  SexO           Hetero            9                3               22               7         34.69    **\<0.001**
  Bi               14              7                9               11                                 
  Homo             12              19               3                5                                 
  E~2~                       113.59 ± 12.70   110.03 ± 13.35   27.56 ± 12.70   25.55 ± 15.32   13.42    **\<0.001**
  T                           0.32 ± 0.23      0.35 ± 0.25      5.12 ± 0.23     5.14 ± 0.28    126.67   **\<0.001**

Note: Demographic data of the study sample. FC, TM, (syn. female-to-male transgender); MC; TW (syn. male-to-female transgender); SexO, sexual orientation based on biological sex; Hetero, heterosexual; Bi, bisexual; Homo, homosexual; E~2~, estrogen in pg/ml; T, testosterone in ng/ml. Age did not differ between groups. Sexual orientation was not equally distributed across groups with mostly heterosexual men and homosexual women. E~2~ and T levels were significantly different across groups (ANOVA, *F* = 13.42 and *F* = 126.67, respectively, both *P* \< 0.001). Post hoc *t*-tests corrected for multiple comparisons revealed differences in E~2~ and T levels between women and men irrespective of gender identity. The normal hormone ranges for E~2~ are 26.70--298.00 and 27.10--52.20 pg/mL and for T are 0.08--0.48 and 2.50--8.40 ng/mL for women and men, respectively ([www.kimcl.at](http://www.kimcl.at), last accessed 19 July 2019). Significant p values are marked in bold.

###### 

Model performances

                                                                                                Group comparisons                                                                           TP   FP   TN   FN      Spec (%)   Sens (%)   FPR     PPV     NPV     AUC         BAC         p~FDR~
  --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ---- ---- ---- ------- ---------- ---------- ------- ------- ------- ----------- ----------- -------------
  Trained models                                                                                Cisgender sex classifier FC versus MC[^a^](#tblfn1){ref-type="table-fn"}                    29   6    28   6       82.35      82.86      17.67   82.86   82.35   0.90        **82.61**   **\<0.001**
  Transgender sex classifier TM versus TW[^b^](#tblfn2){ref-type="table-fn"}                    24                                                                                          11   12   5    52.17   82.76      47.83      68.57   70.59   0.73    **67.47**   **0.04**    
  Gender classifier in all FC + TW versus TM + MC                                               19                                                                                          25   38   39   60.32   32.76      39.68      43.18   49.35   0.49    46.54       0.77        
  Gender classifier in biological male MC versus TW                                             24                                                                                          15   8    10   34.78   70.59      65.22      61.54   44.44   0.57    52.69       0.43        
  Gender classifier in biological female FC versus TM                                           24                                                                                          17   12   11   41.38   68.57      58.62      58.54   52.17   0.53    54.98       0.38        
  Gender incongruence classifier FC + MC versus TM + TW                                         50                                                                                          30   22   19   42.31   72.46      57.69      62.50   53.66   0.58    57.39       0.11        
  Cross-validation                                                                              Cisgender sex classifier[^a^](#tblfn1){ref-type="table-fn"} in transgender TM versus TW     24   7    16   5       69.57      82.76      30.43   77.42   76.19   0.82        76.16       \-
  Transgender sex classifier[^b^](#tblfn2){ref-type="table-fn"} in cisgender FC versus MC       29                                                                                          13   21   6    61.76   82.86      38.24      69.05   77.78   0.85    72.31       \-          
  Validation                                                                                    Cisgender sex classifier[^a^](#tblfn1){ref-type="table-fn"} on depressed FDEP versus MDEP   8    1    12   6       74.07      92.31      66.67   88.89   66.67   0.87        74.73       \-
  Cisgender sex classifier[^a^](#tblfn1){ref-type="table-fn"} on transgender TM versus TW 4w    15                                                                                          3    9    5    75.00   75.00      25.00      83.33   64.29   0.81    75.00       \-          
  Cisgender sex classifier[^a^](#tblfn1){ref-type="table-fn"} on transgender TM versus TW 4m    15                                                                                          3    9    5    75.00   75.00      25.00      83.33   64.29   0.80    75.00       \-          
  Transgender sex classifier[^b^](#tblfn2){ref-type="table-fn"} on depressed FDEP versus MDEP   11                                                                                          9    4    3    30.77   78.57      69.23      55.00   57.14   0.72    54.67       \-          

Note: Model performances evaluated by means of Spec, Sens, false-positive rate (FPR), positive and negative predicted value (PPV and NPV), area under the receiver operating characteristic curve (AUC), and BAC. These measures were computed from the confusion matrix containing the number of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FM). FC; MC; TM (syn. female-to-male transgender); TW (syn. male-to-female transgender); FDEP, female depressed; MDEP, male depressed; 4w, after 4 weeks of cross-sex hormonal treatment; 4m, after 4 months of cross-sex hormonal treatment. *P* values are based on a test where the observed prediction performances for each model were compared to a null distribution of the respective outcome labels by training and cross-validating support vector machine models on *n* = 1000 random label permutations. Model significance was defined at α = 0.05 as *P* = ∑^*n* = 1000^(BAC~observed~ \< BAC~permuted~)/*n*. *P* values were corrected for multiple comparisons using the p~FDR~. Significant p values and BAC are marked in bold.

^a^Sex classifier trained in cisgender individuals

^b^Sex classifier trained in transgender

Study Design {#sec4}
------------

The study was originally designed as a longitudinal monocentric study ([@ref37]) with transgender subjects undergoing structural and functional MRI at three time points: baseline, and then 4 weeks and 4 months after initiation of high-dose cross-sex hormone therapy administration ([ClinicalTrials.gov](http://ClinicalTrials.gov) Identifier: NCT01292785). Before baseline, participants had not undergone any hormonal treatment or sex-reassignment surgery. In parallel, sex- and age-matched control subjects were scanned at similar time points. Data of respective subsamples of subjects have been published in five previous cross-sectional ([@ref37]; [@ref17]; [@ref24], [@ref25]; [@ref69]) and five longitudinal investigations ([@ref26]; [@ref70]; [@ref74]; [@ref39]; [@ref38]). The models created in the current study are based on the structural baseline scans in transgender and control subjects.

MRI Data Acquisition and Preprocessing {#sec5}
--------------------------------------

All participants underwent structural MRI on a 3T whole-body scanner (Siemens Tim Trio) at the Magnetic Resonance Centre of Excellence at the Medical University of Vienna, Austria. A 32-channel head coil and a T1-weighted magnetization-prepared rapid gradient echo sequence (160 slices, 256 × 240 matrix, voxel size 1.1 × 1 × 1 mm^3^, TE = 4.21 ms, TR = 2300 ms, TI = 900 ms; α = 9°; total acquisition time 7 min, 46 s) were used.

MRI preprocessing was performed using the CAT12 toolbox ([@ref19]) for SPM12 v.6685 (Wellcome Trust Center for Neuroimaging, Statistical Parametric Mapping, version 12, <http://www.fil.ion.ucl.ac.uk/spm/software/spm12/>, last accessed 19 July 2019) and MATLAB R2015a (The MathWorks, Inc, 2015, <http://www.mathworks.com/>, last accessed 19 July 2019). First, images were segmented into GM, white matter (WM), and cerebrospinal fluid probability maps. Then, GM maps were registered to Montreal Neurological Institute space and spatially normalized via the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra algorithm ([@ref3]). GM maps were modulated with the default option "modulated normalized" to analyze volumetric patterns differentiating between the target labels as described below. Finally, TIV was estimated. No spatial smoothing was applied as part of the MRI preprocessing because Gaussian smoothing was optimized between 0, 4, and 8 mm within the MVPA pipeline (see details in Supplementary material).

Multivariate Pattern Classification Analysis {#sec6}
--------------------------------------------

Our open-source pattern recognition tool NeuroMiner (version 0.998; ([@ref33]) developed by N.K. was used to implement a fully automated machine learning pipeline to determine sets of predictive neuroanatomical features from the GM maps that best classify the study population according to sex and gender. More specifically, binary classification models were trained to predict: 1) sex in cisgender subjects (FC vs. MC, *N* = 69); 2) sex in transgender subjects (TM vs. TW, *N* = 52); 3) gender identity in all subjects (FC + TM vs. MC + TW, *N* = 121); 4) gender identity in biological females (FC vs. TM, *N* = 64); 5) biological males (MC vs. TW, N = 57); and 6) gender incongruence (FC + MC vs. TM + TW, *N* = 121). Model training and validation was performed using a repeated nested cross-validation (CV) framework as implemented in NeuroMiner, which strictly separated the training process from the evaluation of the predictors' generalization capacity, as detailed previously ([@ref8]; [@ref35]; [@ref34]) and in the Supplementary material. This produced decision scores for each group comparison, which are arbitrary numbers between −1 and 1 measuring the neuroanatomical likeness of being either female versus male (FC vs. MC, TM vs. TW), cis- versus transgender (FC + MC vs. TM + TW) or exhibiting a female or male gender identity (FC vs. TM, MC vs. TW) of each single subject. Every participant obtaining a decision score \>0 belongs to group A and decision scores \< 0 belongs to group B. To test the model significance and generalizability, we determined whether the observed prediction performances for the sex and gender predictors significantly differed from a null distribution of the respective outcome labels by training and cross-validating SVM models on *n* = 1000 random label permutations ([@ref36]). Model significance was defined at α = 0.05 as *P* = ∑^*n* = 1000^(balanced accuracy \[BAC\]~observed~ \< =BAC~permuted~)/*n*, where BAC = (sensitivity + specificity)/2. *P* values were corrected for multiple comparisons using the false discovery rate (p~FDR~) ([@ref6]).

To validate significant models further, we adopted two different approaches: using a crossover machine learning design, we tested whether the sex classifier trained on cisgender subjects could predict sex in transgender subjects and vice versa. Moreover, to determine the construct and discriminant validity of our models, we applied our cis- and transgender sex classifier on an independent data set of female and male medication-naïve patients suffering from major depression (*N* = 27). Furthermore, the cisgender sex classifier was applied on parts of our transgender sample (*N* = 32) for whom serial MRI scans were available after 4 weeks and 4 months of cross-sex hormonal treatment, respectively, to determine the influence of treatment on the individual expression of the discriminative pattern over time. The sample to which the respective classification model was applied was processed identically to the sample on which the models were created as described above. For further information regarding both validation samples see Supplementary material.

Additionally, we adopted a classical univariate approach with our data for comparison with our MVPA findings. Univariate data processing and results are detailed in the Supplementary material.

Statistical Analyses {#sec7}
--------------------

Descriptive statistics and further analyses were performed in IBM SPSS v25, MATLAB R2015a, and R v3.

Results {#sec8}
=======

Demographic Data {#sec9}
----------------

No statistically significant differences regarding age were observed between groups (*F*~(3)~ = 1.71, *P* = 0.17, ANOVA, see [Table 1](#TB1){ref-type="table"}). Regarding the distribution of sexual orientation and hormone levels, see [Table 1](#TB1){ref-type="table"} and Supplementary material.

Neuroanatomical Classification of Biological Sex {#sec10}
------------------------------------------------

The neuroanatomical sex classifier trained on the cisgender participants (FC vs. MC) correctly separated biological women from men with a cross-validated BAC of 82.6% (specificity, Spec = 82.4% and sensitivity, Sens = 82.9%; for more details, see [Table 2](#TB2){ref-type="table"}). The model was highly significant (p~FDR~ \< 0.001 after permutation testing). In contrast, the sex classifier trained on the transgender sample (TM vs. TW) provided a cross-validated BAC of 67.5% (p~FDR~ = 0.04, Spec = 52.2%, Sens = 82.8%), corresponding to a significantly lower classification performance than the cisgender sex classifier (*χ*^2^ = 10, *P* \< 0.001, see Supplementary material).

The neuroanatomical patterns distinguishing between both sexes and chosen by 95% of the models of each classification, respectively, are displayed in [Figure 1](#f1){ref-type="fig"}.

![Voxel selection probability maps of cis- and transgender sex classifiers. Red/blue areas indicate volume increments/reductions in (*A*) cisgender female versus male (FC vs. MC) and (*B*) TM versus TW. Accordingly, red = F \> M and blue = F \< M. To visualize the average decision function, we used a method described previously ([@ref35]). The colored areas shown represent voxels that contribute with a probability of 80% to the average neuroanatomical decision boundary in the respective model trained, overlaid on the single-subject MNI template using the software MRIcroGL ([https://www.nitrc.org/projects/mricrogl](http://www.nitrc.org/projects/mricrogl), last accessed 19 July 2019).](bhz170f1){#f1}

In cisgender individuals, the neuroanatomical decision function involved less GM in men versus women covering the superior, medial, and inferior frontal cortex; the anterior and middle cingulate cortex; the middle temporal and superior occipital cortex; the lingual, fusiform, parahippocampal, and calcarine cortex; the post- and precentral cortex; the caudate, hippocampus, insula, and the thalamus as well as parts of the cerebellum. Less GM volume (GMV) in women versus men was more limited and localized in the middle frontal cortex, the inferior and superior parietal cortex, superior temporal and fusiform cortex, and the cerebellum. In transgender subjects, less GM in men versus women was observed in the inferior, superior, and middle frontal cortex; the anterior, middle, and posterior cingulate cortex; the insula; the thalamus; the precuneus and calcarine; the hippocampus and fusiform cortex; the caudate; the angular and supramarginal cortex; the pre- and postcentral cortex; and the precuneus and middle occipital cortex. Less GMV in women versus men was limited to the cerebellum (see [Fig. 1](#f1){ref-type="fig"}). Although both sex classifier patterns partly overlap (caudate, hippocampus, and fusiform gyrus, see [Fig. 2](#f2){ref-type="fig"}), the most striking differences can be observed in the insula, anterior cingulate cortex, thalamus, frontal gyrus, and precuneus regions appearing to depict a significantly more pronounced pattern in discriminating between women in men in transgender as compared to cisgender individuals (see [Fig. 2](#f2){ref-type="fig"}).

![Overlay of voxel selection probability maps of cis- and transgender sex classifiers. Voxel selection probability maps shown in red represent the absolute values (positive and negative) of the voxels that reliably contributed to the classification of FC versus MC. The map in blue depicts the absolute values (positive and negative) of the relevant voxels for the classification between TM versus TW. The overlapping regions between the two classifiers are shown in magenta (bilateral caudate, hippocampus, fusiform gyrus).](bhz170f2){#f2}

Neuroanatomical Prediction Performance of Gender Identity and Gender Incongruence {#sec11}
---------------------------------------------------------------------------------

The neuroanatomical gender identity classifier did not successfully separate individuals with a female gender identity (FC + TW) from individuals with a male gender identity (MC + TM; BAC = 46.5%, Spec = 60.3%, Sens = 32.8%, p~FDR~ = 0.77, [Table 2](#TB2){ref-type="table"}). Accordingly, no separation could be found when splitting the sample with respect to biological sex, namely FC versus TM (BAC = 55.0%, p~FDR~ = 0.38, Spec = 41.4%, Sens = 68.6%) and MC versus TW (BAC = 52.7%, p~FDR~ = 0.43, Spec = 34.8%, Sens = 70.6%). Similarly, no significant gender incongruence classifier could be trained on the whole sample separating cis- and transgender individuals (FC + MC vs. TM + TW, BAC = 57.4%, p~FDR~ = 0.11, Spec = 42.3%, Sens = 72.5%, see [Table 2](#TB2){ref-type="table"}).

Validation of the Sex Classifiers {#sec12}
---------------------------------

First, using the crossover machine learning design, the cisgender sex classifier separated biological women and men in the transgender sample with a BAC of 76.2% (Spec = 69.6%, Sens = 82.8%, see [Table 2](#TB2){ref-type="table"}) that was not significantly different from the classification performance in the cisgender sample (BAC = 82.6%, McNemar's χ2 = 2.64, *P* = 0.10). Conversely, the transgender sex classifier applied to the cisgender individuals correctly differentiated both sexes with a BAC of 72.3% (Spec = 61.8%, Sens = 82.9%, see [Table 2](#TB2){ref-type="table"}), which was also similar to the classification performance in the transgender sample (BAC = 67.5%, McNemar's χ2 = 1.96, *P* = 0.20).

Secondly, the cisgender sex classifier model was tested on a subset of the transgender sample following 4 weeks and 4 months of cross-sex hormonal treatment. The cisgender sex classifier performed slightly but significantly worse at both time points with a BAC of 75.0% (Spec = 75.0%, Sens = 75.0%, McNemar's χ2 = 12.64, *P* \< 0.001) in the transgender sample after 4 weeks and a BAC of 75.0% (Spec = 75.0%, Sens = 75.0%, McNemar's χ2 = 12.64 *P* \< 0.001) after 4 months of treatment compared to baseline before treatment (BAC = 76.2%). Further details on this analysis are provided in the Supplementary material and [Supplementary Figure 1*A*--*D*](#sup1){ref-type="supplementary-material"}.

Finally, the cis- and transgender sex classifier models were adopted on an independent sample of medication-naïve patients suffering from major depression. When applying the cisgender sex classifier, depressed women and men were correctly classified with a BAC of 74.7% (Spec = 74.1%, Sens = 92.3%, similar to the performance in nondepressed cisgender subjects with McNemar's χ2 = 1.96, *P* = 0.16). Conversely, the transgender sex classifier performed significantly worse (McNemar's χ2 = 16.83, *P* \< 0.001) in predicting sex in the sample of depressed patients (BAC = 54.7%, Spec = 30.8%, Sens = 78.6%, see also [Supplementary Figure 1*E*](#sup1){ref-type="supplementary-material"}).

Discussion {#sec13}
==========

We investigated the sex- and gender-related neuroanatomical differences in cis- and transgender individuals by analyzing structural MRI data using machine learning. As initially hypothesized, the binary classification models trained in our sample of 121 subjects correctly classified women and men in cisgender subjects (FC vs. MC, *N* = 69) with a BAC of 83% and in transgender subjects (TM vs. TW, *N* = 52) with a BAC of 68%. In fact, this difference in BAC of 15% corresponds to a significantly lower sex classification performance in transgender subjects. The determined significant cis- and transgender sex classifier could be validated when applied to the transgender (BAC = 76%) and cisgender samples (BAC = 72%), respectively. When externally validating our classifiers in a sample of depressed patients, the cisgender classifier still produced a BAC of 75%, while the transgender sex classifier performed significantly worse (BAC = 55%, see Supplementary material). When applying the cisgender sex classifier to the subgroup of transgender participants receiving hormone treatment, a small yet significant change in prediction performance could be observed (baseline BAC = 76%, BAC after 4 weeks of treatment = 75%, BAC after 4 months of treatment = 75%, see also Supplementary material). We could not confirm our hypothesis that neuroanatomical classification would allow to distinguish male or female gender identity independently of the biological sex of a given person or the presence of gender incongruence.

Sex {#sec14}
---

To the best of our knowledge, this is the first study to show a significantly lower classification performance in transgender compared to cisgender individuals related to biological sex implying an interaction between biological sex and gender identity at the neuroanatomical level. The performance of our cisgender sex classifier replicates recent studies reporting on a single-person separability of the biological sex of 83% in a derivation sample and 77% in a replication sample by analyzing cortical thickness using machine learning ([@ref71]). Our findings are also in keeping with another study investigating sex differences in cis- and transgender youth (age \< 19 years) using MVPA that showed a prediction accuracy of sex in cisgender subjects of 88%. Although a specific transgender sex classification (TM vs. TW) was not performed in this work, untreated TM and TW could be separated from MC (accuracy of 78%) and FC (accuracy of 86%), respectively, implying that sex can be predicted irrespective of gender identity ([@ref28]).

The widespread volumetric patterns underlying our sex classification models (see [Fig. 1](#f1){ref-type="fig"}) primarily involved areas of increased GMV in female versus male participants except for the cerebellum that showed the opposite effect. Interestingly, a previous study on the same dataset described decreased intrahemispheric structural connections of subcortical/limbic to frontal and temporal areas in TM in comparison with TW and cisgender individuals ([@ref24]). This might elucidate a balancing mechanism, in which brain volume is enlarged to compensate for less communication between areas in transgender individuals with female natal sex. As for the cerebellum, it appears to be consistently discriminating to biological sex regardless of gender identity. A study on 2-year cross-sex hormone-treated transgender showed that this structure is bilaterally larger in cisgender male than in cisgender female and TM even after at least 2 years of therapy ([@ref52]).

Even though our study was performed using structural data, it is of note that the most striking differences between the voxel probability maps of both sex classifiers were observed in regions belonging to the resting-state fMRI salience network ([@ref50]), namely the anterior cingulate cortex and the insula, and the default mode network ([@ref61]), namely the prefrontal, cingulate, precuneal, and hippocampal cortices. This finding is not surprising considering that both networks are thought to be responsible for connecting bodily perceptions and emotional states, self-reference, emotion of one's self, theory of mind and social behavior, and self-awareness, respectively. The role of the insula acting as a key mediator of the subjective experience of emotions evoked by internal bodily sensations is especially noteworthy in this context ([@ref59]; [@ref78]). [@ref75]) showed alterations in the insular cortex of untreated TW and speculated that these are related to the neural network of body perception and reflect the distress accompanying gender incongruence. It seems quite intuitive that the process of reflection about one's self and the physical perception of one's self is highly sex-specific and changed in persons experiencing an incongruent gender identity and natal sex ([@ref56]).

The stability of our sex classifiers (cis- and transgender) was further underlined by the findings of our CV analysis, resulting in unchanged classification performance in both ways. However, as shown in [Supplementary Figure 1*B*](#sup1){ref-type="supplementary-material"}, the distribution of the decision scores produced by the cisgender sex classification model was less discriminative in transgender individuals. Specifically, the decision scores of TW subjects were shifted toward the positive range (=female) of the histogram implying a higher variability in sexually differing brain patterns in these subjects, in other words a less stable sex pattern in TW subject. This "feminization" of TW brain patterns is supported by several postmortems and structural MRI reports ([@ref81]; [@ref40]; [@ref18]; [@ref72]; [@ref83]); however, not all studies necessarily support this notion ([@ref46]; [@ref67]; [@ref23]). Additionally, we showed that the cisgender sex classifier was significantly less accurate when applied on the treated transgender sample across time (see [Table 2](#TB2){ref-type="table"}). When looking in depth at the distribution of the decision scores ([Supplementary Fig. 1*C*,*D*](#sup1){ref-type="supplementary-material"}), again the TW scores were shifted in the "female" range, while TM scores remained largely unchanged over time. Numerically, the BAC decreased only by \~1% at both 4 weeks and 4 months of treatment compared to baseline; however, this decrease was significant and solely driven by effects of cross-sex hormone therapy in TW subjects. This is in line with previous findings by our group in the same sample showing significant volume decreases in the right hippocampus in TW subjects after 16 weeks of hormone administration compared to baseline, but no changes in TM subjects ([@ref70]). Effects in TM participants might be only visible after a more prolonged treatment time ([@ref55]), as evident in a recent study in which the mean neuroanatomical volume for the amygdala, putamen, and corpus callosum differed between TM and FC after gender affirming surgery and at least 2 years of cross-sex hormone therapy ([@ref52]). The same group reported a correlation of androgens and local functional connectivity in long-term (\>80 months) treated TM in the cerebellum and frontal regions, an association that was not detected in TW with estrogens ([@ref53]). Other authors have reported regional increases in cortical thickness associated with testosterone in TM subjects following 6 months of hormonal treatment. Estrogens and antiandrogens were associated with cortical thickness increments in TW ([@ref82]). Our findings imply a higher sensitivity of male brain structure to the influence of cross-sex hormonal treatment, mirrored in the decreased capacity of the cisgender sex classifier to separate female and male subjects in the treated transgender sample.

Finally, the strength of our cisgender sex classification model was confirmed when applied on depressed women and men (see Supplementary material), which was not true for our transgender sex classifier indicating a considerable spatial overlap between the sex differing brain regions selected by the transgender classifier and brain regions affected by brain pathology associated with depression, for instance, the insula, the amygdala, the anterior cingulate cortex, and the posterior cingulate cortex ([@ref12]; [@ref43]).

Gender and Gender Incongruence {#sec15}
------------------------------

We did not detect a neuroanatomical pattern that separates individuals with a female and male gender identity (FC + TW vs. TM + MC, FC vs. TM, MC vs. TW). This is in agreement with the study performed by [@ref28]) who---using a similar methodology in adolescents---could not determine a gender identity signature on whole-brain voxel level separating FC from TM and MC from TW, respectively. On the other hand, this stands in contrast to previously published studies using univariate statistical analyses and gender incongruence as a model to show distinct regional differences between transgender and control subjects sharing the same biological sex (namely FC and TM, MC and TW) ([@ref46]; [@ref67]; [@ref72]; [@ref75]).

Furthermore, here, we were not able to detect a distinct neuroanatomical signature of gender incongruence (FC + MC vs. TM + TW). Previous studies comparing the brain structure of cis- versus untreated transgender individuals using MRI are limited and inconsistent in regard the direction of change and the brain regions associated with male and female gender identity ([@ref73]). [@ref72]) showed higher GMV in cisgender subjects in the cerebellum, left angular gyrus, and left inferior parietal lobule as compared to transgender subjects (TW and TM) independently from their biological sex. [@ref67]) reported decreased GMV in the thalamus and putamen and increased GMV and the right insular, inferior frontal, and right angular gyrus in TW compared to both cisgender women and men. [@ref46]) showed that the brain structure of TW subjects more closely resembles individuals sharing their natal sex (MC) than their gender identity (FC) apart from the right putamen that was shown to be significantly larger in TW compared to MC. Consistently, gender incongruence was associated with brain anatomical findings as shown previously in postmortem studies for the INAH-1 ([@ref18]) and the size ([@ref81]) and neuron number ([@ref40]) of the red nucleus of the stria terminalis.

In fact, the MVPA performed in this study was not designed to identify such region-specific and small differences but rather to detect widespread brain structural pattern carrying discriminative value. As such, even though our model was not able to define such patterns when investigating gender identity or gender incongruence, we cannot exclude that region-specific volume differences in male and female gender identity are present. Gender identity might exhibit---if any---a considerably more subtle and regional GMV signature, which is potentially masked by prominent sex effects. Potentially, gender identity might require a certain degree of smoothing in the data in order to be captured by the algorithm. On the other hand, such gender identity effects might be more strongly associated with WM patterns and structural and functional connectivity alterations, which can be measured using DTI and resting-state fMRI. This is backed by fMRI studies showing specific hormone-induced resting-state connectivity patterns that are different from the assigned and aspired sex in treated TW ([@ref53]; [@ref11]). Also, weaker structural and functional connectivity between the anterior cingulate-precuneus and the right occipito-parietal cortex was recently reported in TW and TM compared to cisgender controls ([@ref49]). Additionally, using univariate methods and other MRI modalities, deviating WM fiber tracts ([@ref37]; [@ref62]), altered structural connectivity ([@ref24]) and functional connectivity ([@ref42]) have been described in transgender subjects, which supports further research in this direction.

To our knowledge, the only previously published MVPA of sex and gender identity, including both cis- and transgender subjects, did not compute a gender incongruence classification to enable a comparison with our data ([@ref28]).

Limitations {#sec16}
-----------

There are a few limitations to our analysis that need to be addressed. First of all, additional clinical and psychometric data to further characterize our transgender sample (e.g., education, quality of life, and depression scales for all participants including the cisgender sample) and disentangle neuroanatomical effects driven by gender incongruence or the associated psychological distress would be desirable. Future research should consider further clinical variables to account for potential subsyndromal depressive symptoms or other conditions related to gender incongruence. We would like to emphasize that at variance to previous reports we did include cis- and transgender individuals with divergent sexual orientation (hetero-, homo-, and bisexual) and provide data on hormonal levels that were considered in our analysis. At the same time, however, the inclusion of study populations with divergent sexual orientation might represent an additional bias. Although we made efforts to exclude a potential influence of sexual orientation (see Supplementary material), we cannot definitely rule out that the effects of gender incongruence on our GMV-based sex classifier (less-pronounced sexual dimorphism in transgender individuals) might be overlapping with effects driven by sexual orientation as homosexuality was shown to be associated with less cerebral sexual differentiation in WM tracts ([@ref9]; [@ref48], [@ref49]). Future research in this direction should consider balancing the groups according to sexual orientation or including heterosexual cis- and transgender populations only.

Secondly, due to the limited sample size in our transgender sample, we were not able to perform an external validation of the gender incongruence classifier, which will be subject to future research. By increasing the sample size, also a better representation of the psychiatric comorbidities can be delineated, reaching better generalizability of our findings in daily clinical settings. Also, the external validation sample of depressed patients used here was measured on a different MR scanner. While we cannot rule out certain scanner effects, we assume that these do not explain the fact that the transgender sex classifier performed significantly worse than the cisgender sex classifier in predicting sex in the depressed sample as they would interfere with both models in a similar way.

Conclusions {#sec17}
===========

A better understanding of neurobiological sex differences in terms of prevalence discrepancies, differing disease trajectories and outcomes in diverse psychiatric conditions is indispensable ([@ref10]). Research dealing with gender issues in neuroscience claims that our brains are individual mosaics of female and male characteristics, thereby rejecting the simplistic idea of a "female" or "male" brain ([@ref47]; [@ref29]). In light of this general rethinking, our findings support previously published evidence demonstrating that the brain structure of transgender people partially converges on an assumed sex continuum, although we cannot conclude from our findings that it resembles the morphology of the respective gender identity ([@ref76]; [@ref68]). Further studies using MVPA and other data modalities are needed to determine whether this entity is rather reflected in brain connectivity or WM. Generally, we can conclude from our analysis that sex has a major effect on GM irrespective of the self-perception of being a woman or a man. Also, in contrast to previous univariate analyses, structural brain changes in regard to sex are not limited to single areas but involve multiple regions and brain networks. Clinically, it would now be of major interest to assess whether transgender persons exhibit long-term brain structural change when receiving cross-sex hormonal treatment and thereby experience a shift to a risk profile for certain brain diseases in their gender identity. Ideally, further longitudinal studies using a pooled transgender sample and multiple imaging modalities should be envisaged to clarify the matter. Finally, in comparison with univariate analyses performed on the same datasets, our findings provide novel relevant insights into basic human biology in the context of brain morphological sex differences and gender identity reflected in brain structure.
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